Molecular imaging of SFRP2 expression may provide a rapid, non-invasive method to monitor tumor regression during therapy for angiosarcoma, and contributes to our understanding of the biology of SFRP2 during tumor progression. This evidence concerns the gene SFRP2 and angiosarcoma.